NO20061246L - Salter og polymorfe former av en pyrrol-substituert indolinonforbindelse - Google Patents

Salter og polymorfe former av en pyrrol-substituert indolinonforbindelse

Info

Publication number
NO20061246L
NO20061246L NO20061246A NO20061246A NO20061246L NO 20061246 L NO20061246 L NO 20061246L NO 20061246 A NO20061246 A NO 20061246A NO 20061246 A NO20061246 A NO 20061246A NO 20061246 L NO20061246 L NO 20061246L
Authority
NO
Norway
Prior art keywords
salts
pyrrole
polymorphic forms
indolinone compound
substituted indolinone
Prior art date
Application number
NO20061246A
Other languages
English (en)
Norwegian (no)
Inventor
Andrei Blasko
Qingwu Jin
Qun Lu
Michael Anthony Mauragis
Dian Song
Brenda Sue Vonderwell
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20061246L publication Critical patent/NO20061246L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20061246A 2003-10-02 2006-03-17 Salter og polymorfe former av en pyrrol-substituert indolinonforbindelse NO20061246L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50810403P 2003-10-02 2003-10-02
PCT/IB2004/003070 WO2005033098A1 (en) 2003-10-02 2004-09-20 Salts and polymorphs of a pyrrole-substituted indolinone compound

Publications (1)

Publication Number Publication Date
NO20061246L true NO20061246L (no) 2006-03-29

Family

ID=34421700

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061246A NO20061246L (no) 2003-10-02 2006-03-17 Salter og polymorfe former av en pyrrol-substituert indolinonforbindelse

Country Status (26)

Country Link
US (1) US7247627B2 (ja)
EP (1) EP1670785B1 (ja)
JP (1) JP4933259B2 (ja)
KR (2) KR20060058728A (ja)
CN (1) CN100432072C (ja)
AR (1) AR047762A1 (ja)
AT (1) ATE473223T1 (ja)
AU (1) AU2004277464B2 (ja)
BR (1) BRPI0415022A (ja)
CA (1) CA2540639C (ja)
CY (1) CY1110771T1 (ja)
DE (1) DE602004028028D1 (ja)
DK (1) DK1670785T3 (ja)
ES (1) ES2348623T3 (ja)
HK (1) HK1093068A1 (ja)
IL (1) IL174414A (ja)
MX (1) MXPA06003661A (ja)
NO (1) NO20061246L (ja)
NZ (1) NZ546001A (ja)
PL (1) PL1670785T3 (ja)
PT (1) PT1670785E (ja)
RU (1) RU2319702C2 (ja)
SI (1) SI1670785T1 (ja)
TW (1) TW200524921A (ja)
WO (1) WO2005033098A1 (ja)
ZA (1) ZA200602691B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
MX2007011767A (es) * 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
EP1928462A1 (en) * 2005-09-20 2008-06-11 Pfizer Products Incorporated Dosage forms and methods of treatment using a tyrosine kinase inhibitor
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
JP5531613B2 (ja) * 2007-04-04 2014-06-25 大塚化学株式会社 チタン酸カリウム及びその製造方法並びに摩擦材及び樹脂組成物
CN102159570B (zh) * 2008-09-17 2014-01-15 诺瓦提斯公司 N-[6-(顺式-2,6-二甲基吗啉-4-基)吡啶-3-基]-2-甲基-4’-(三氟甲氧基)[1,1’-联苯]-3-甲酰胺的盐
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9851313B2 (en) * 2015-03-03 2017-12-26 Panalytical B.V. Quantitative X-ray analysis—ratio correction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534522A (en) * 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
EA005996B1 (ru) * 2000-02-15 2005-08-25 Сьюджен, Инк. Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
CN100364991C (zh) * 2001-08-15 2008-01-30 法玛西雅厄普约翰美国公司 2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
YU67702A (sh) 2001-09-28 2004-12-31 Pfizer Products Inc. Postupak za dobijanje alkansulfonil piridina
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
AU2003216282A1 (en) * 2002-02-15 2003-09-09 Pharmacia And Upjohn Company Llc Process for preparing indolinone derivatives
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound

Also Published As

Publication number Publication date
JP2007507482A (ja) 2007-03-29
WO2005033098A8 (en) 2006-04-20
PT1670785E (pt) 2010-09-16
EP1670785A1 (en) 2006-06-21
MXPA06003661A (es) 2006-06-05
JP4933259B2 (ja) 2012-05-16
CN100432072C (zh) 2008-11-12
CY1110771T1 (el) 2015-06-10
CN1863796A (zh) 2006-11-15
WO2005033098A9 (en) 2006-05-26
ES2348623T3 (es) 2010-12-09
AR047762A1 (es) 2006-02-22
ATE473223T1 (de) 2010-07-15
WO2005033098A1 (en) 2005-04-14
AU2004277464A1 (en) 2005-04-14
TW200524921A (en) 2005-08-01
BRPI0415022A (pt) 2006-11-28
PL1670785T3 (pl) 2010-12-31
ZA200602691B (en) 2007-06-27
CA2540639C (en) 2010-08-31
KR20080007520A (ko) 2008-01-21
US7247627B2 (en) 2007-07-24
EP1670785B1 (en) 2010-07-07
DK1670785T3 (da) 2010-10-18
IL174414A (en) 2011-12-29
RU2006110541A (ru) 2006-08-27
RU2319702C2 (ru) 2008-03-20
KR20060058728A (ko) 2006-05-30
US20050118255A1 (en) 2005-06-02
AU2004277464B2 (en) 2010-07-08
DE602004028028D1 (de) 2010-08-19
NZ546001A (en) 2009-09-25
HK1093068A1 (en) 2007-02-23
SI1670785T1 (sl) 2010-10-29
CA2540639A1 (en) 2005-04-14
IL174414A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
NO20061246L (no) Salter og polymorfe former av en pyrrol-substituert indolinonforbindelse
NO2019005I1 (no) N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter
NO20071290L (no) Enantiomert rene aminoheteroarylforbindelser som protein kinase inhibitorer
GB2431927A9 (en) 1,2-Disubstituted indoles & derivatives thereof astherapeutic 5-iipoxygenase-activating protein (fl ap) inhibitors
UA107175C2 (uk) Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
RS54607B1 (en) 5-SUBSTITUATED HINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS
EA200801381A1 (ru) Производные пиримидина
NO20082445L (no) Neuropeptid-2 reseptor-agonister
ATE433968T1 (de) Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf)
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
IL165687A0 (en) Methods for synthesis of acyloxyalkyl derivatives of gaba analogs
EA201000486A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу (flap)
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
SI1713801T1 (sl) Postopek priprave 1-(2S,3S)-2-benzhidril-N-(5-terc-butil-2-metoksibenzil)kinuklidin-3- amina
EA200970041A1 (ru) Ингибиторы акт (протеинкиназы в)
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
EA200970604A1 (ru) Новое промежуточное соединение и способ, используемый для получения {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
EP1628974A4 (en) HYDANTOIN DERIVATIVES AS INHIBITORS OF THE TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE)
EA200600330A1 (ru) Замещённые имидазопиримидины для предупреждения и лечения рака
NO20054071L (no) Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
ATE405588T1 (de) Analoge des somatostatin
NO20080866L (no) Faststoff saltformer av pyrrol-substituert 2-indolinon
MXPA04003085A (es) Proceso estereoespecifico para sintesis de derivados de 2-il cromano.
CY1112539T1 (el) Νεες ενωσεις μορφινης για φαρμακευτικες συνθεσεις

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application